Monkeypox drug trial: can tecovirimat speed up healing?
NCT ID NCT05559099
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether the drug tecovirimat is safe and effective for treating monkeypox (mpox). About 600 adults and children with confirmed mpox and active skin lesions took either tecovirimat or a placebo for 14 days, along with standard care. The main goal was to see how quickly their lesions healed. The trial is now complete.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MONKEYPOX are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
L'Hôpital Général de Référence de Kole
Kole, Democratic Republic of the Congo
-
L'Hôpital Général de Référence de Tunda
Tunda, Democratic Republic of the Congo
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smallpox vaccine stop mpox in its tracks?
- Experimental drug targets smallpox and monkeypox after exposure
- Monkeypox vaccine immune response under the microscope
- Can a pill speed up monkeypox recovery? major trial underway
- Scientists investigate mpox in severely weakened immune systems
- Could a smaller dose of monkeypox vaccine work just as well?